- Home
- DXC vs TNDM Comparison
DXC vs TNDM Comparison
Compare DXC & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DXC
- TNDM
- Stock Information
- Founded
- DXC 1959
- TNDM 2006
- Country
- DXC United States
- TNDM United States
- Employees
- DXC N/A
- TNDM N/A
- Industry
- DXC EDP Services
- TNDM Medical/Dental Instruments
- Sector
- DXC Technology
- TNDM Health Care
- Exchange
- DXC Nasdaq
- TNDM Nasdaq
- Market Cap
- DXC 3.3B
- TNDM 2.7B
- IPO Year
- DXC N/A
- TNDM 2013
- Fundamental
- Price
- DXC $21.28
- TNDM $34.81
- Analyst Decision
- DXC Hold
- TNDM Buy
- Analyst Count
- DXC 10
- TNDM 15
- Target Price
- DXC $20.30
- TNDM $53.27
- AVG Volume (30 Days)
- DXC 1.5M
- TNDM 1.3M
- Earning Date
- DXC 11-07-2024
- TNDM 11-06-2024
- Dividend Yield
- DXC N/A
- TNDM N/A
- EPS Growth
- DXC N/A
- TNDM N/A
- EPS
- DXC 0.42
- TNDM N/A
- Revenue
- DXC $13,457,000,000.00
- TNDM $796,002,000.00
- Revenue This Year
- DXC N/A
- TNDM $21.53
- Revenue Next Year
- DXC N/A
- TNDM $11.81
- P/E Ratio
- DXC $50.43
- TNDM N/A
- Revenue Growth
- DXC N/A
- TNDM 0.72
- 52 Week Low
- DXC $14.79
- TNDM $13.82
- 52 Week High
- DXC $25.14
- TNDM $53.69
- Technical
- Relative Strength Index (RSI)
- DXC 60.20
- TNDM 29.10
- Support Level
- DXC $19.83
- TNDM $35.16
- Resistance Level
- DXC $20.32
- TNDM $38.94
- Average True Range (ATR)
- DXC 0.54
- TNDM 2.02
- MACD
- DXC 0.05
- TNDM -0.58
- Stochastic Oscillator
- DXC 95.71
- TNDM 7.89
About DXC DXC Technology Company
DXC Technology Co is a vendor-independent IT services provider. The company's operating segment includes Global Business Services (GBS) and Global Infrastructure Services (GIS). It generates maximum revenue from the GIS segment. GIS offerings include Cloud and Security; IT Outsourcing and Modern Workplace. Geographically, it derives a majority of revenue from the Other Europe region.
About TNDM Tandem Diabetes Care Inc.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for diabetes patients. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on a tubeless pump. Nearly three-quarters of total revenue is derived from the us, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one third is from disposable infusion sets that need to be changed over every 2 to 3 days.